NEIL2 and lung cancer: Cases with mutations (assuming loss of function) or CNV alterations (all CNV loss, other than 1 CNV gain lung cancer case) in NEIL2 displayed decreased OS in liver hepatocellular carcinoma and decreased DFS in bladder urothelial and lung squamous cell carcinoma (Figure 2D).